Featured Research

from universities, journals, and other organizations

Celebrex inhibits burden of skin cancer in high-risk patients, research finds

Date:
January 6, 2010
Source:
American Association for Cancer Research
Summary:
People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon.

People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon.

Related Articles


According to results of a placebo-controlled, randomized, double-blind, Phase II study, the use of celecoxib was effective in inhibiting the development of basal cell carcinomas in a relatively rare group of patients who are highly susceptible to carcinoma. These findings are published in the January issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

Celecoxib, sold under the brand name of Celebrex by Pfizer Inc., is a non-steroidal anti-inflammatory drug (NSAID). Patients with Gorlin syndrome typically develop hundreds or even thousands of basal cell carcinomas in their lifetime.

Ervin H. Epstein Jr., M.D., senior scientist at the Children's Hospital of Oakland Research Institute, Oakland, Calif., said the goal of this study was to reduce the number of basal cell carcinomas in patients with this rare disorder who are most at risk for this form of cancer.

"The underlying idea is if we can find something in these high-risk patients that could be translatable to the 'normal' population, then we could ultimately use that form of chemoprevention to reduce the numbers of skin cancer in all people," he said.

Epstein and colleagues randomized 60 patients with basal cell carcinoma to receive either 200 mg of oral celecoxib two times a day or placebo. After about two years, patients who received placebo had a 50 percent increase in basal cell carcinoma per year compared with a 20 percent increase among those who received celecoxib.

"We found some beneficial effect of preventing tumors in patients treated with the NSAID," Epstein said.

Furthermore, there was no difference in the rate or severity of side effects between patients in either group.

In a separate editorial, also published in the January issue of Cancer Prevention Research, Charles M. Rudin, M.D., Ph.D., wrote that "this new study of cyclooxygenase inhibition, together with recent data on the efficacy of the hedgehog pathway inhibition, offer new hope for patients at a high risk for basal cell cancer."

"Basal cell carcinoma is an incredibly common disease, far and away the most common cancer in people. The potential for a therapy that would impact the incidence of this would be huge," said Rudin, associate director for clinical research at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins.

Rudin told the American Association for Cancer Research that while the clinical results of this study do not have an immediate impact for patients with basal cell carcinoma, Epstein and colleagues have set a precedent for future clinical trials.

So how do these findings translate to the clinic?

In another accompanying editorial, also published in the same issue of Cancer Prevention Research, Jack L. Arbiser, M.D., Ph.D., wrote that these results demonstrate a pivotal role in the pathogenesis of basal cell carcinoma and point towards combination therapy among those with this form of cancer.

"This has implications for public health," said Arbiser, professor of dermatology in the Department of Dermatology at Emory University School of Medicine.

Although the results of this study showed positive results in reducing cancer, Epstein suggested that concerns remain about the potential cardiovascular side effects (i.e., stroke or heart attack) that may be associated with this drug. More studies are needed to validate the safety and efficacy of the use of celecoxib in this population.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jean Y. Tang, Michelle Aszterbaum, Mohammad Athar, Franco Barsanti, Carol Cappola, Nini Estevez, Jennifer Hebert, Jimmy Hwang, Yefim Khaimskiy, Arianna Kim, Ying Lu, Po-Lin So, Xiuwei Tang, Michael A. Kohn, Charles E. McCulloch, Levy Kopelovich, David R. Bickers, and Ervin H. Epstein, Jr. Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed PTCH1 /- Humans and Mice. Cancer Prevention Research, 2010; 3 (1): 25 DOI: 10.1158/1940-6207.CAPR-09-0200

Cite This Page:

American Association for Cancer Research. "Celebrex inhibits burden of skin cancer in high-risk patients, research finds." ScienceDaily. ScienceDaily, 6 January 2010. <www.sciencedaily.com/releases/2010/01/100105095840.htm>.
American Association for Cancer Research. (2010, January 6). Celebrex inhibits burden of skin cancer in high-risk patients, research finds. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2010/01/100105095840.htm
American Association for Cancer Research. "Celebrex inhibits burden of skin cancer in high-risk patients, research finds." ScienceDaily. www.sciencedaily.com/releases/2010/01/100105095840.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins